To determine the effects of FOXM1 inhibition on LSCs enriched population, we treated the MA9.3 cells, MA9.3/NRAS cells, CD34+ stem/progenitor cells from AML patients as well as normal CD34+ stem/progenitor cells with Siomycin A or FOXM1-specific ARF26-44 peptide or mutant ARF37–44 peptide. Here, CD34 is linked to acute myeloid leukemia.